Lateral Dx
Lateral Dx is a UK-based contract services company providing lateral flow assay development, manufacturing, and consultancy for in vitro diagnostics, serving B2B customers across human, veterinary, agricultural, aquaculture, and food safety sectors globally.
- Company typePrivate
- Founded2019
- HeadquartersAlloa, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Lateral Dx does
Lateral Dx is a privately held UK contract services company founded in 2019 by Richard Campbell and headquartered in Alloa, Scotland. The firm specializes in lateral flow assay (LFA) development, manufacturing, and consultancy for in vitro diagnostic applications, serving B2B customers across human diagnostics (cardiac markers, infectious disease, inflammation, women's health hormones), veterinary diagnostics (canine heartworm, parvovirus, Giardia), agriculture/farming (toxins, crop pests, allergens), aquaculture (seafood disease detection), and food safety. Customers are located across the UK, US, Europe, and Asia, and 70 diverse projects have been completed since incorporation. The firm is ISO 9001:2015 certified and recognized as a UK Life Sciences Innovator (2023).
Lateral Dx firmographics
Firmographics- Name
- Lateral Dx
- Legal name
- Lateral Dx Ltd
- Website
- https://lateraldx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lateral Dx is a UK-based contract services company providing lateral flow assay development, manufacturing, and consultancy for in vitro diagnostics, serving B2B customers across human, veterinary, agricultural, aquaculture, and food safety sectors globally.
- Ownership category
- akta.pro rank
Lateral Dx industry classification
Industry- Product category
- Contract Lateral Flow Assay Development and Manufacturing Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ)
- akta.pro secondary industry
- Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
Keywords
Where Lateral Dx is headquartered
LocationHeadquarters
- HQ city
- Alloa
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Lateral Dx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Lateral Flow Development: Phased rapid test development service covering Proof of Principle, Feasibility, Optimisation, Validation, and Manufacture stages. Customers own the complete design history file for their lateral flow assay.
- Contract Lateral Flow Test Manufacture: High quality small or large scale manufacture of lateral flow assays and rapid tests. Includes advice on automation, process efficiency, training, and scale-up.
- Consultancy Services: Technical, regulatory and market expertise for point of care testing systems. Includes advice on regulatory and quality systems relating to in vitro diagnostic solutions.
- Rapid Antibody Screening: Quantitative lateral flow screening service to select best antibody pairings. Cost-effective method delivering actionable results in 1-2 weeks.
- Antibody Conjugation: From R&D to production scale conjugation services. Available in Mini, Midi and Production scales.
- Reagent and Material Supply: Gold colloid (20nm, 40nm, 60nm, 80nm), gold conjugates (anti-mouse IgG, anti-IgY, anti-biotin, Protein-A), and custom antibody conjugation products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom contract services with bespoke packages |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
Lateral Dx product offering
Product offeringCore offering
Lateral Dx provides contract services for the development, conjugation, and manufacture of lateral flow assays (rapid diagnostic tests) and supplies related reagents such as gold colloid nanospheres. Its offerings are organised across phased lateral flow development (Proof of Principle through Validation), contract manufacturing, a proprietary Rapid Antibody Screening service, antibody-to-particle conjugation, point-of-care diagnostics consultancy, and reader-integrated development using the Cube Reader and RDS-2500 quantitative readers.
Product overview
Lateral Dx is a specialist contract service provider in lateral flow assay development and in vitro diagnostic solutions. The company offers a comprehensive service portfolio organized around five core offerings: Contract Lateral Flow Development (spanning Proof of Principle through Manufacture phases), Contract Lateral Flow Test Manufacture, Rapid Antibody Screening (a proprietary quantitative screening technology), Antibody Conjugation services (conjugating to gold nanoparticles, fluorescent particles, cellulose nanobeads, polystyrene, and carbon), and Reagent/Material Supply (including Gold Colloid Nanospheres in 20-80nm sizes). Additional services include Consultancy and reader-based development using Cube Reader and RDS-2500 systems. The company serves human diagnostics, veterinary, farming, aquaculture, and environmental testing sectors.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Lateral Flow Development Phased rapid test development service spanning Proof of Principle, Feasibility, Optimisation, Validation, and Manufacture phases, allowing customers to own the complete design history file for their lateral flow assay. Targeted at healthcare, veterinary, environmental and food safety partners building point-of-care diagnostic tests.
- Contract Lateral Flow Test Manufacture High quality small or large scale manufacture of lateral flow assays and rapid tests, including advice on automation, process efficiency, training, and scale-up. For partner businesses needing outsourced lateral flow production.
- Consultancy Technical, regulatory, and market expertise for point-of-care testing systems, including advice on regulatory and quality systems relating to in vitro diagnostic solutions. For diagnostic developers needing expert guidance on lateral flow programs.
- Rapid Antibody Screening Quantitative lateral flow-based screening service to select the best antibody pairings, working with as little as 0.1 mg antibody quantities, screening 10 antibodies (100 combinations), at one-tenth the cost of standard methods, and delivering actionable results in 1–2 weeks. For diagnostic developers needing fast, cost-effective antibody pair selection.
- Antibody Conjugation Conjugation of antibodies and antigens to gold colloid (passive and covalent), gold nanoparticles, cellulose nanobeads, polystyrene (latex), gold nanorods, fluorescent particles and dyes, carbon, and gold nanoshells. Available from R&D through to production scale (Mini, Midi and Production). For diagnostic developers needing signal-particle conjugation.
- Reagent and Material Supply Direct supply of gold colloid (20nm, 40nm, 60nm, 80nm), gold conjugates (anti-mouse IgG, anti-IgY, anti-biotin, Protein-A), antibodies (IgY/anti-IgY), and custom antibody conjugation products. For lateral flow test developers and manufacturers.
- Gold Colloid Nanospheres High quality gold colloid nanospheres in 20, 40, 60 and 80 nm sizes at OD1, OD5 and OD10 concentrations, QC tested using UV/VIS Spectroscopy and Transition Emission Microscopy (TEM) analysis for use in antibody conjugation in lateral flow assays.
- Cube Reader Development Services Contract development service using the Optricon Cube Reader — a portable 40g reader that delivers quantitative and qualitative results within 3 seconds and supports cloud data storage, usable with test strips without housing.
- RDS-2500 Reader Development Services Contract development service using the RDS-2500 reader — a handheld portable instrument providing fully quantitative results with high-precision strip detection in 5 seconds, multi-spectral detection, Wi-Fi/USB connectivity, image capture, and cloud data management.
- Visual Score Card A free scoring tool that lets users assign numeric values (1–10) to test and control line intensities for quantitative comparison and data analysis of gold colloid-based lateral flow tests.
Quantifiable outcome
- Antibody screening cost reduced to 1/10th standard methods
- +5 more outcomes
Companies that use Lateral Dx
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
Lateral Dx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Lateral Dx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BBI SolutionsflagshipStrategic partnership to deliver fully integrated lateral flow diagnostic solutions. Lateral Dx leads assay design and optimization using advanced antibody screening, reader technologies, novel materials, and quantitative capabilities. BBI Solutions provides end-to-end ISO 13485-certified manufacturing, quality assurance, and regulatory support from Crumlin facilities. The collaboration addresses growing demand for rapid point-of-care diagnostics across human health, veterinary, environmental, and food safety sectors, enabling customers to move from concept to commercial-scale production with reduced timelines and enhanced performance. A major commercial program is planned for 2026.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Lateral Dx competitors and assessment
Company assessmentDirect peers
- Cytodiagnostics: Specialist provider of gold nanoparticles and conjugation services for lateral flow assay development. Directly comparable to Lateral Dx's gold colloid nanosphere product line and antibody conjugation services.
- DCN Diagnostics: US-based contract development and manufacturing organization specializing in lateral flow assay development, conjugation, and reader integration. Directly comparable service portfolio and customer base in lateral flow diagnostics.
- Abingdon Health: UK-headquartered lateral flow contract development and manufacturing organization offering end-to-end services from assay development through scale-up manufacture. Directly comparable to Lateral Dx as a lateral flow CDMO serving similar diagnostics customers with similar contract-based service model.
- Innova Biosciences (now part of Expedeon / Abcam): Specialist in antibody conjugation to gold nanoparticles and lateral flow assay development reagents. Highly comparable to Lateral Dx's antibody conjugation and gold colloid reagent offerings.
- BBI Solutions: UK-based manufacturer of lateral flow diagnostic tests and immunoassay reagents with ISO 13485 commercial manufacturing. Now Lateral Dx's strategic partner, BBI is a direct lateral flow peer with overlapping assay development and manufacturing capabilities.
Broad incumbents
- SD Biosensor: Korean IVD company with a major lateral flow and rapid test manufacturing portfolio spanning infectious disease, cardiac markers, and clinical chemistry. Comparable end-product categories to Lateral Dx's customer outputs but operating as a large global incumbent rather than a contract developer.
- Merck KGaA / Sigma-Aldrich: Global life science tools and reagents supplier offering gold nanoparticles, diagnostic reagents, and assay development components. Overlaps with Lateral Dx's reagent and material supply business as part of a broad portfolio.
- Bio-Rad Laboratories: Large established life science tools and diagnostics company offering a broad portfolio including immunoassay reagents and lateral flow test development components. Overlaps with Lateral Dx's reagent supply and assay development services as part of a much wider portfolio.
- QuidelOrtho: Major in vitro diagnostics company with significant lateral flow test product portfolio across infectious disease, women's health, and specialty diagnostics. Comparable end-product market to Lateral Dx's customer outputs but at much larger scale.
Emerging players
- ArcDia International: Finland-based developer of rapid immunoassay and lateral flow diagnostic platforms. Comparable focus on lateral flow and point-of-care diagnostics, though with a stronger emphasis on proprietary end-product reader technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Lateral Dx social profiles
Digital presenceLateral Dx compliance and trust
Trust signalCompliance1 record
Lateral Dx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lateral Dx leadership team
Management profileNumber of profiles
Profiles8 records
Lateral Dx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lateral Dx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lateral Dx
What does Lateral Dx do?
Lateral Dx provides contract services for the development, conjugation, and manufacture of lateral flow assays (rapid diagnostic tests) and supplies related reagents such as gold colloid nanospheres. Its offerings are organised across phased lateral flow development (Proof of Principle through Validation), contract manufacturing, a proprietary Rapid Antibody Screening service, antibody-to-particle conjugation, point-of-care diagnostics consultancy, and reader-integrated development using the Cube Reader and RDS-2500 quantitative readers.
Is Lateral Dx a public or private company?
Lateral Dx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lateral Dx founded?
Lateral Dx was founded in 2019. It employs 11 to 50 people.
Where is Lateral Dx based?
Lateral Dx is headquartered in Alloa, United Kingdom, in the Europe region.
How does Lateral Dx make money?
Six revenue lines are on record. Contract Lateral Flow Development is the primary driver. The others are contract Lateral Flow Test Manufacture, consultancy Services, rapid Antibody Screening, antibody Conjugation and reagent and Material Supply.
Who are Lateral Dx's main competitors?
Direct peers on record are Cytodiagnostics, DCN Diagnostics, Abingdon Health, Innova Biosciences (now part of Expedeon / Abcam) and BBI Solutions. Broad incumbents are SD Biosensor, Merck KGaA / Sigma-Aldrich, Bio-Rad Laboratories and QuidelOrtho. ArcDia International is listed as an emerging player.
Does Lateral Dx have an API?
No public API is recorded for Lateral Dx.
What industry is Lateral Dx in?
Lateral Dx's product category is Contract Lateral Flow Assay Development and Manufacturing Services. Its primary akta.pro industry code is HLAHAAAJ, Companion Diagnostics (CDx) & Precision Medicine IVD, with a secondary code of HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support. Its NAICS code is 325413 and its SIC code is 2835.